newsfilter
← Latest News
GlobeNewswire·

Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development

-1L ESCC confirmed ORR of 75% irrespective of PD-L1 status, confirmed ORR of 100% for PD-L1- positive, in evaluable patients- -2L ESCC durable clinical benefit observed with a clear dose-response irrespective of PD-L1